Peptide vaccine study for advanced pancreatic or colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests a personalized vaccine made from a patient’s tumor to help the immune system recognize and attack cancer. It is for people with advanced pancreatic or colorectal cancer (often after surgery or while metastatic) and aims to see if the approach is safe and can help immune control of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with advanced pancreatic cancer or advanced colorectal cancer
- Your cancer is metastatic, or for pancreatic cancer you may be localized and scheduled for main tumor removal
- You can provide enough tumor tissue (biopsy or surgery sample) for the vaccine to be personalized
- You feel well enough for treatment (ECOG performance status 0–1) and are expected to live at least 9–12 months depending on the study group
- You can safely have this kind of treatment with acceptable blood/organ function, and you can sign consent
- You must not have certain health conditions (like HIV, brain metastases, serious autoimmune disease, major lung inflammation, hepatitis B/C, or major uncontrolled heart problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
This trial tests a personalized cancer vaccine (ODI-2001) combined with standard chemotherapy in patients with advanced colon or pancreatic cancer that cannot be surgically removed. The vaccine is designed specifically for each patient's tumor to help their immune system fight the cancer.
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This trial tests a new tumor vaccine combined with a standard chemotherapy regimen (AG) for people with metastatic pancreatic cancer. It aims to see if the combination is safe and helps the immune system fight the cancer.
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.